Developer docs
API playgroundTry for free, no card

Search company profiles

DynamiCure

Full company profile

uuid0008q4d

Namestring
DynamiCure
Legal namestring
DynamiCure Biotechnology, LLC
Websiteurl
dynamicure.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

DynamiCure is a privately held, pre-revenue biopharmaceutical company founded in July 2019 by Dr. Lieping Chen of Yale University and headquartered in Waltham, Massachusetts. The company is developing a pipeline of therapeutic monoclonal antibody candidates based on an immuno-normalization platform, with its core focus on the DC-6001 anti-CD93 program. DynamiCure's scientific thesis centers on blocking CD93, a receptor downstream of VEGF-A, to normalize abnormal tumor vasculature rather than simply inhibiting angiogenesis. This approach aims to reduce tumor hypoxia and convert immunosuppressive tumor microenvironments into immunostimulatory ones, with the goal of enhancing the efficacy of existing immunotherapies and chemotherapeutic agents.

The company's lead candidate, DCBY02, is a monoclonal antibody targeting a specific CD93 epitope that demonstrated distinct in vitro and in vivo properties and anti-tumor activity in preclinical studies. The FDA cleared an IND for DCBY02 in August 2022, and the company dosed first patients in a multicenter, open-label Phase 1 trial in November 2022 evaluating the candidate across multiple advanced or metastatic solid tumor indications, including colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical, head and neck cancers, and glioblastoma multiforme. A second anti-CD93 antibody, DCSZ11, targets a different CD93 epitope and is advancing toward IND submission expected in Q4 2022. DynamiCure also has an autoimmune disease program built around an undisclosed target licensed from Dr. Chen's research, extending the immuno-normalization concept beyond oncology.

The business model is a traditional clinical-stage biopharmaceutical structure. The company has worldwide exclusive commercial licenses from Yale University and the University of Colorado Anschutz Medical Campus for CD93 and other novel targets, obtained through co-development partnerships with scientific founders Drs. Lieping Chen and Yuwen Zhu. DynamiCure operates full in-house R&D and integrated CMC capabilities from a 17,000 square foot laboratory facility in Waltham, with plans to commercialize products through traditional pharmaceutical channels or licensing partnerships upon regulatory approval. As a pre-revenue company with 11–50 employees, DynamiCure's go-to-market is clinical trial execution at academic cancer centers across North America, supported by scientific publications, press releases, and engagement with the medical community.

Short descriptiontext

DynamiCure is a pre-revenue biopharmaceutical company developing monoclonal antibody candidates that target the CD93 pathway to normalize tumor vasculature in cancer and treat autoimmune diseases. Founded in 2019 and headquartered in Waltham, Massachusetts, with lead candidate DCBY02 in Phase 1 clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics, monoclonal antibodies, immuno-normalization, biopharmaceutical development, clinical stage research
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue biopharmaceutical company expecting to generate revenue through commercialization of therapeutic antibody products upon regulatory approval. Revenue would come from sales of proprietary antibody drugs for treatment of cancer and autoimmune diseases.

dynamicure.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DynamiCure is a clinical-stage biopharmaceutical company developing a pipeline of monoclonal antibody therapeutic candidates targeting the CD93 pathway to normalize tumor vasculature and convert immunosuppressive tumor microenvironments into immunostimulatory ones. The company's lead asset DCBY02 is in Phase 1 clinical trials for advanced solid tumors, while a second candidate DCSZ11 is advancing toward IND submission. The pipeline also includes an undisclosed autoimmune disease program, with the company leveraging exclusive worldwide licenses from Yale University and University of Colorado.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 1 trial evaluating DCBY02 in up to 36 participants (Part 1 dose-escalation) and up to 60 participants (Part 2 dose-expansion)
+1 more record
Product overview1 text field

DynamiCure is a biopharmaceutical company developing a pipeline of innovative therapeutic antibody candidates with first-in-class and best-in-class potential. The company's core focus is the DC-6001 anti-CD93 program, which consists of two monoclonal antibodies—DCBY02 and DCSZ11—each targeting different epitopes of the CD93 receptor. DCBY02 is currently in Phase 1 clinical trials for advanced solid tumors, while DCSZ11 is advancing toward IND submission. The company employs a platform-agnostic approach to translate immuno-normalization insights into therapeutics for oncology and autoimmune disease, with full in-house drug discovery and development capabilities including CMC capabilities.

Product and service3 records
1DCBY02
CategoryOncology Biopharmaceutical - Monoclonal Antibody
Description

Lead anti-CD93 monoclonal antibody candidate that normalizes malignant tumor vasculature and converts the tumor microenvironment from immunosuppressive to immunostimulatory. Currently in Phase 1 clinical development for advanced/metastatic solid tumors including colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical, head and neck cancers, and glioblastoma multiforme.

2DCSZ11
CategoryOncology Biopharmaceutical - Monoclonal Antibody
Description

Second monoclonal antibody candidate from the DC-6001 program targeting a different epitope of the CD93 receptor than DCBY02. Demonstrated distinct in vitro and in vivo properties and anti-tumor activity in pre-clinical development. IND submission expected Q4 2022.

3DC-6001 Anti-CD93 Program
CategoryOncology Biopharmaceutical - Therapeutic Development Program
Description

DynamiCure's anti-CD93 development program consisting of two monoclonal antibodies (DCBY02 and DCSZ11), each blocking different epitopes of the CD93 receptor. Designed to enhance efficacy of immunotherapies and chemotherapeutic agents by normalizing tumor vasculature.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-10-01
Description

DynamiCure obtained exclusive worldwide commercial licenses from University of Colorado for CD93 and other novel targets from Dr. Yuwen Zhu's research. Dr. Zhu, Associate Professor of Surgical Oncology, focuses on normalizing tumor vasculature to improve drug and immune system access to tumors. Ongoing collaboration continues for additional research programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-01
Description

DynamiCure was founded by Dr. Lieping Chen from Yale University. The company has obtained exclusive worldwide commercial licenses from Yale for several novel targets resulting from Dr. Chen's research, including CD93. The company continues to collaborate with Yale laboratories on additional research programs.

3Dr. Lieping Chen
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific co-founder of DynamiCure, Dr. Chen is a world-renowned immunologist and oncologist at Yale University. His pioneering work uncovered the immunosuppressive role of the PD-1/PD-L1 pathway. He is United Technologies Corporation Professor in Cancer Research at Yale and co-leader of the Cancer Immunology Program at Yale Cancer Center. Elected to Academia Sinica of Taiwan and US National Academy of Sciences.

dynamicure.com
4Dr. Yuwen Zhu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaborator whose work focuses on normalizing tumor vasculature to improve pathways to tumors. Associate Professor of Surgical Oncology at University of Colorado Anschutz Medical Campus, with prior cancer immunotherapy research at Johns Hopkins Medical and Yale University.

dynamicure.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DynamiCure

Oncology Biopharmaceuticalsdynamicure.com

DynamiCure is a pre-revenue biopharmaceutical company developing monoclonal antibody candidates that target the CD93 pathway to normalize tumor vasculature in cancer and treat autoimmune diseases. Founded in 2019 and headquartered in Waltham, Massachusetts, with lead candidate DCBY02 in Phase 1 clinical trials.

What DynamiCure does

DynamiCure is a privately held, pre-revenue biopharmaceutical company founded in July 2019 by Dr. Lieping Chen of Yale University and headquartered in Waltham, Massachusetts. The company is developing a pipeline of therapeutic monoclonal antibody candidates based on an immuno-normalization platform, with its core focus on the DC-6001 anti-CD93 program. DynamiCure's scientific thesis centers on blocking CD93, a receptor downstream of VEGF-A, to normalize abnormal tumor vasculature rather than simply inhibiting angiogenesis. This approach aims to reduce tumor hypoxia and convert immunosuppressive tumor microenvironments into immunostimulatory ones, with the goal of enhancing the efficacy of existing immunotherapies and chemotherapeutic agents.

The company's lead candidate, DCBY02, is a monoclonal antibody targeting a specific CD93 epitope that demonstrated distinct in vitro and in vivo properties and anti-tumor activity in preclinical studies. The FDA cleared an IND for DCBY02 in August 2022, and the company dosed first patients in a multicenter, open-label Phase 1 trial in November 2022 evaluating the candidate across multiple advanced or metastatic solid tumor indications, including colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical, head and neck cancers, and glioblastoma multiforme. A second anti-CD93 antibody, DCSZ11, targets a different CD93 epitope and is advancing toward IND submission expected in Q4 2022. DynamiCure also has an autoimmune disease program built around an undisclosed target licensed from Dr. Chen's research, extending the immuno-normalization concept beyond oncology.

The business model is a traditional clinical-stage biopharmaceutical structure. The company has worldwide exclusive commercial licenses from Yale University and the University of Colorado Anschutz Medical Campus for CD93 and other novel targets, obtained through co-development partnerships with scientific founders Drs. Lieping Chen and Yuwen Zhu. DynamiCure operates full in-house R&D and integrated CMC capabilities from a 17,000 square foot laboratory facility in Waltham, with plans to commercialize products through traditional pharmaceutical channels or licensing partnerships upon regulatory approval. As a pre-revenue company with 11–50 employees, DynamiCure's go-to-market is clinical trial execution at academic cancer centers across North America, supported by scientific publications, press releases, and engagement with the medical community.

DynamiCure firmographics

Firmographics
Name
DynamiCure
Legal name
DynamiCure Biotechnology, LLC
Website
https://dynamicure.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
DynamiCure is a pre-revenue biopharmaceutical company developing monoclonal antibody candidates that target the CD93 pathway to normalize tumor vasculature in cancer and treat autoimmune diseases. Founded in 2019 and headquartered in Waltham, Massachusetts, with lead candidate DCBY02 in Phase 1 clinical trials.
Ownership category
akta.pro rank

Where DynamiCure is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DynamiCure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue biopharmaceutical company expecting to generate revenue through commercialization of therapeutic antibody products upon regulatory approval. Revenue would come from sales of proprietary antibody drugs for treatment of cancer and autoimmune diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

DynamiCure product offering

Product offering

Core offering

DynamiCure is a clinical-stage biopharmaceutical company developing a pipeline of monoclonal antibody therapeutic candidates targeting the CD93 pathway to normalize tumor vasculature and convert immunosuppressive tumor microenvironments into immunostimulatory ones. The company's lead asset DCBY02 is in Phase 1 clinical trials for advanced solid tumors, while a second candidate DCSZ11 is advancing toward IND submission. The pipeline also includes an undisclosed autoimmune disease program, with the company leveraging exclusive worldwide licenses from Yale University and University of Colorado.

Product overview

DynamiCure is a biopharmaceutical company developing a pipeline of innovative therapeutic antibody candidates with first-in-class and best-in-class potential. The company's core focus is the DC-6001 anti-CD93 program, which consists of two monoclonal antibodies—DCBY02 and DCSZ11—each targeting different epitopes of the CD93 receptor. DCBY02 is currently in Phase 1 clinical trials for advanced solid tumors, while DCSZ11 is advancing toward IND submission. The company employs a platform-agnostic approach to translate immuno-normalization insights into therapeutics for oncology and autoimmune disease, with full in-house drug discovery and development capabilities including CMC capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • DCBY02 Lead anti-CD93 monoclonal antibody candidate that normalizes malignant tumor vasculature and converts the tumor microenvironment from immunosuppressive to immunostimulatory. Currently in Phase 1 clinical development for advanced/metastatic solid tumors including colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical, head and neck cancers, and glioblastoma multiforme.
  • DCSZ11 Second monoclonal antibody candidate from the DC-6001 program targeting a different epitope of the CD93 receptor than DCBY02. Demonstrated distinct in vitro and in vivo properties and anti-tumor activity in pre-clinical development. IND submission expected Q4 2022.
  • DC-6001 Anti-CD93 Program DynamiCure's anti-CD93 development program consisting of two monoclonal antibodies (DCBY02 and DCSZ11), each blocking different epitopes of the CD93 receptor. Designed to enhance efficacy of immunotherapies and chemotherapeutic agents by normalizing tumor vasculature.

Quantifiable outcome

  • Phase 1 trial evaluating DCBY02 in up to 36 participants (Part 1 dose-escalation) and up to 60 participants (Part 2 dose-expansion)
  • +1 more outcomes

Companies that use DynamiCure

Customer profile

Segments2 records

Ideal customer profiles3 records

DynamiCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DynamiCure partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • University of Colorado Anschutz Medical CampuscoreStrategic or Co-development Partner · 1 October 2019DynamiCure obtained exclusive worldwide commercial licenses from University of Colorado for CD93 and other novel targets from Dr. Yuwen Zhu's research. Dr. Zhu, Associate Professor of Surgical Oncology, focuses on normalizing tumor vasculature to improve drug and immune system access to tumors. Ongoing collaboration continues for additional research programs.
  • Yale UniversitycoreStrategic or Co-development Partner · 1 July 2019DynamiCure was founded by Dr. Lieping Chen from Yale University. The company has obtained exclusive worldwide commercial licenses from Yale for several novel targets resulting from Dr. Chen's research, including CD93. The company continues to collaborate with Yale laboratories on additional research programs.
  • Dr. Lieping ChencoreStrategic or Co-development PartnerScientific co-founder of DynamiCure, Dr. Chen is a world-renowned immunologist and oncologist at Yale University. His pioneering work uncovered the immunosuppressive role of the PD-1/PD-L1 pathway. He is United Technologies Corporation Professor in Cancer Research at Yale and co-leader of the Cancer Immunology Program at Yale Cancer Center. Elected to Academia Sinica of Taiwan and US National Academy of Sciences.
  • Dr. Yuwen ZhucoreStrategic or Co-development PartnerResearch collaborator whose work focuses on normalizing tumor vasculature to improve pathways to tumors. Associate Professor of Surgical Oncology at University of Colorado Anschutz Medical Campus, with prior cancer immunotherapy research at Johns Hopkins Medical and Yale University.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

DynamiCure competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

DynamiCure social profiles

Digital presence

DynamiCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DynamiCure leadership team

Management profile

Number of profiles

Profiles3 records

DynamiCure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DynamiCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DynamiCure

What does DynamiCure do?

DynamiCure is a clinical-stage biopharmaceutical company developing a pipeline of monoclonal antibody therapeutic candidates targeting the CD93 pathway to normalize tumor vasculature and convert immunosuppressive tumor microenvironments into immunostimulatory ones. The company's lead asset DCBY02 is in Phase 1 clinical trials for advanced solid tumors, while a second candidate DCSZ11 is advancing toward IND submission. The pipeline also includes an undisclosed autoimmune disease program, with the company leveraging exclusive worldwide licenses from Yale University and University of Colorado.

Is DynamiCure a public or private company?

DynamiCure is a private company. It is classified as unknown and is currently operating.

When was DynamiCure founded?

DynamiCure was founded in 2019. It employs 11 to 50 people.

Where is DynamiCure based?

DynamiCure is headquartered in Waltham, United States, in the North America region.

How does DynamiCure make money?

One revenue line is on record: pharmaceutical Product Sales.

Does DynamiCure have an API?

No public API is recorded for DynamiCure.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure BiotechnologyImaginAb Inc. has signed a multi-year, non-exclusive license and supply agreement with DynamiCure Biotechnology to provide clinical doses of its investigational CD8 ImmunoPET™ imaging agent for use in DynamiCure's clinical trials. The agreement allows DynamiCure to leverage ImaginAb's proprietary technology in its immuno-oncology clinical programs targeting cancer and autoimmune disorders. ImaginAb's CEO indicated the company remains on track to gain regulatory approval for the CD8 ImmunoPET™ technology, which is currently in Phase II clinical trials.GlobeNewswireDynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced CancersDynamiCure dosed the first patients in its Phase 1 trial of DCBY02, an anti-CD93 antibody, in adults with advanced solid tumors. The trial assesses safety and anti-tumor activity in dose-escalation and expansion phases. The company expects to submit an IND for its second anti-CD93 candidate, DCSZ11, in the fourth quarter.BioSpaceDynamiCure Announces Appointment of Industry Veteran Peter Lasky as its First Chief People OfficerDynamiCure appointed Peter Lasky as its first Chief People Officer, leading HR functions including talent acquisition and diversity. Lasky previously served as Senior Vice President, Human Resources at Deciphera Pharmaceuticals. He will support the company's clinical development of its lead candidate.GlobeNewswireDynamiCure Announces Appointment of Industry Veteran Peter Lasky as its First Chief People OfficerDynamiCure appointed Peter Lasky as its first Chief People Officer, leading HR functions including talent acquisition and diversity. Lasky previously served as SVP of HR at Deciphera Pharmaceuticals and held similar roles at Wave Life Sciences, Sekisui Diagnostics, and Shire Pharmaceuticals. He will support the company's clinical development of its lead candidate.GlobeNewswireDynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical DevelopmentDynamiCure received FDA IND clearance to advance its first anti-CD93 antibody candidate, DCBY02, into a Phase 1 study for adult patients with advanced cancers. The study will evaluate safety and efficacy, with a dose-escalation phase followed by expansion. DynamiCure plans to submit the IND for its second candidate, DCSZ11, in Q4 2022.